Dyne Therapeutics receives financial advice from WilmerHale for up to $505 million in debt and equity financing deals.
Dyne Therapeutics, a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, has successfully secured up to $505 million in debt and equity capital. This substantial financing, which includes a $275 million senior secured debt component, was facilitated by the legal expertise of WilmerHale.
WilmerHale, a renowned law firm, served as legal counsel to Dyne Therapeutics, providing invaluable guidance and expertise in structuring and executing complex financial transactions. The firm played a pivotal role in navigating the legal aspects of senior secured debt financing and possibly an underwritten public offering.
The WilmerHale loan facility team, led by Stuart Falber and Scott Lunin, consisted of Nathan Moore, George Shuster, Alex Dean, Jamie Wolfe, Lorri Strizich, Victoria Peluso, Michelle Sidle, Amy O'Connell, Conor Gutierrez, and Abi King. Each team member brought their unique skills to the table, with Nathan J. Moore contributing to the debt financing aspects and Scott Lunin advising on equity financing matters, including any underwritten public offerings.
Stuart M. Falber, as Co-Chair of the Life Sciences Group, provided strategic guidance throughout the financing process, leveraging his extensive experience in life sciences corporate and securities law.
In addition to the loan facility, Dyne Therapeutics also secured a concurrent $230 million underwritten public offering of common stock. The loan facility closed on June 27, 2025, and the equity financing closed on July 2, 2025. The financing was further bolstered by a $100 million term loan and four additional contingent term loan tranches totaling up to $175 million.
The debt financing consisted of a $275 million senior secured debt with Hercules Capital, Inc. This substantial investment will undoubtedly aid Dyne Therapeutics in its mission to develop and bring to market innovative therapies for individuals living with genetically driven neuromuscular diseases.
This successful financing round underscores the importance of legal counsel in complex financial transactions, particularly in the life sciences sector. WilmerHale's expertise and guidance were instrumental in Dyne Therapeutics' ability to secure the necessary resources to continue its groundbreaking work.
WilmerHale's legal expertise was crucial in structuring and executing the complex financial transactions for Dyne Therapeutics, including the senior secured debt financing and potential underwritten public offerings in the finance sector. The successful financing round totaling up to $505 million, which included a $275 million senior secured debt component, was greatly aided by WilmerHale's counsel.
